Undisclosed asthma COPD DPI / Transpire Bio - LARVOL DELTA

Transpire Bio Announces Progress in Clinical Development with Initiation of a New Human Subject Study for Asthma and COPD Inhaled Drug Program (GlobeNewswire) - "Transpire Bio Inc...today announced the commencement of a new human subject study for its inhalation therapy program targeting asthma and chronic obstructive pulmonary disease (COPD). This advancement builds on the promising results from a previous clinical study and reflects the company’s commitment to improving the lives of individuals affected by these respiratory conditions."

New trial • Asthma • Chronic Obstructive Pulmonary Disease

Transpire Bio Achieves Important Corporate Milestone with Completion of First Human Subject Study in the Company’s Asthma and Chronic Obstructive Pulmonary Disease Inhaled Drug Program (GlobeNewswire) - "Transpire Bio...announced that the company has completed the first human subject study of its inhalation product for the treatment of asthma and chronic obstructive pulmonary disease (COPD)....'The completion of our first clinical study is an important milestone for Transpire Bio and represents a significant step toward our goal of becoming a world-leading inhalation medicines company...'"

Trial completion • Asthma • Chronic Obstructive Pulmonary Disease • Pulmonary Disease • Respiratory Diseases